MBX Biosciences (MBX) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed Zai Lab (ZLAB) over the past year, gaining 235.8% versus a loss of 26.4%. Zai Lab is the larger company by market cap ($2.83 billion vs $2.54 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | ZLAB |
|---|---|---|
| Share price | $52.81 | $25.24 |
| Market cap | $2.54B | $2.83B |
| 1-day change | -0.83% | +1.73% |
| YTD return | +68.83% | +40.65% |
| 1-year return | +235.75% | -26.36% |
| 5-year return | — | -75.68% |
| EPS (TTM) | $-2.37 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $460.16M |
| Revenue growth (YoY) | — | +15.33% |
| Net income (latest FY) | $-87.00M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | — | -49.86% |
| Net margin | — | -38.15% |
| 52-week high | $72.64 | $32.76 |
| 52-week low | $12.94 | $15.96 |
| Distance from 52-week high | -27.30% | -22.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +78.56% | +31.30% |
| Average volume | 534.13K | 945.51K |
| Shares outstanding | 48.16M | 112.27M |
| Employees | 63 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed ZLAB by 262.1 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
MBX vs ZLAB FAQ
Which is bigger, MBX Biosciences or Zai Lab?
Zai Lab (ZLAB) is larger, with a market capitalization of $2.83B compared with $2.54B for MBX Biosciences (MBX).
Which stock has performed better over the past year, MBX or ZLAB?
MBX returned +235.75% over the past 12 months, compared with -26.36% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.